A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
This is a Phase III, two-arm, randomized, double-blind placebo-controlled study in participants with HER2-positive primary breast cancer who have received preoperative chemotherapy and HER2-directed therapy, including trastuzumab followed by surgery, with a finding of residual invasive disease in the breast and/or axillary lymph nodes.
As of June 4, 2024, this study is no longer accepting any newly screened participants.
Inclusion Criteria:
Exclusion Criteria:
Buena, California 91505, United States
Carrollton, Georgia 30117, United States
Philadelphia, Pennsylvania 19106, United States
San Antonio, Texas 78229, United States
São Paulo, São Paulo 01317-001, Brazil
Sofia, 1527, Bulgaria
Wuhan, 430022, China
Praha 4 - Krc, 140 59, Czechia
Westerstede, 26655, Germany
Crete, 711 10, Greece
New Delhi, National Capital Territory of Delhi 110085, India
North WEST Delhi, National Capital Territory of Delhi 110088, India
Ratnagiri Kilminnal, Tamil Nadu 632517, India
Gda?sk, 80-214, Poland
Cluj County, 407280, Romania
Moscow, Moscow Oblast 115478, Russia
Moscow, Moscow Oblast 143422, Russia
Moskva, Moscow Oblast 111123, Russia
Kazan, Republic of Karelia 420029, Russia
Saint Peterburg, Sankt-Peterburg 191104, Russia
Saint Petersburg, Sankt-Peterburg 197758, Russia
Saint Petersburg, Sankt-Peterburg 197758, Russia
Edirne, 22030, Turkey (Türkiye)
Kharkiv, Kharkiv Governorate 61070, Ukraine
Sumy, Kholm Governorate 40005, Ukraine
Dnipropetrovsk, 49102, Ukraine